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Abstract
Introduction: There is new emphasis on identifying and treating HIV in the first days of life and also an appreciation that low
birth weight (LBW) and preterm delivery (PTD) frequently accompany HIV-related pregnancy. Even in the absence of HIV, PTD
and LBW contribute substantially to neonatal and infant mortality. HIV-exposed and -infected infants with these characteristics
have received little attention thus far. As HIV programs expand to meet the 90-90-90 target for ending the HIV pandemic,
attention should focus on newborn infants, including those delivered preterm or of LBW.
Discussion: In high prevalence settings, infant diagnosis of HIV is usually undertaken after the neonatal period. However, as
in utero infection may be diagnosed at birth, earlier initiation of therapy may limit viral replication and prevent early damage.
Globally, there is growing awareness that preterm and LBW infants constitute a substantial proportion of births each year.
Preterm infants are at high risk for vertical transmission. Feeding difficulties, apnoea of prematurity and vulnerability to sepsis
occur commonly. Feeding intolerance, a frequent occurrence, may compromise oral administration of medications. Although
there is growing experience with post-exposure prophylaxis for HIV-exposed term newborn infants, there is less experience with
preterm and LBW infants. For treatment, there are even fewer options for preterm infants. Only zidovudine has adequate dosing
recommendations for treating term and preterm infants and has an intravenous formulation, essential if feeding intolerance
occurs. Nevirapine dosing for prevention, but not treatment, is well established for both term and preterm infants.
HIV diagnosis at birth is likely to be extremely stressful for new parents, more so if caring for preterm or LBW infants. Programs
need to adapt to support the medical and emotional needs of young infants and their parents, where interventions may be
lifesaving.
Conclusions: New focus is required for the newborn baby, including those born preterm, with LBW or small for gestational age
to consolidate gains already made in early diagnosis and treatment of young children.
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Introduction
The Joint United Nations Program on HIV/AIDS (UNAIDS)
was established in 1996 to lead global efforts for universal
access to prevention, treatment, care and support [1]. There
has been much progress, with increased access to care, reduc-
tion in vertical transmission and reversal of mortality trends.
In 2014, UNAIDS released the 90-90-90 policy document,
which defines new global targets to consolidate gains and
ultimately end the pandemic. The aims are as follows: iden-
tifying HIV in 90% of the infected population, of whom
90% should be placed on combination antiretroviral therapy
(cART), of whom 90% should be virally suppressed [2].
Newborn infants are an important target group that includes
the most neglected population of all  those with low birth
weight (LBW) and/or preterm delivery (PTD). Collectively,
these infants are the last frontier for HIV management
in terms of knowledge and experience. Paradoxically, as they
are developmentally the youngest and most fragile popula-
tion, they also represent the first frontier to be encountered.
We comment on the current state of knowledge, areas re-
quiring increased attention under the present circumstances
and research. We also seek to heighten awareness in health-
care workers of challenges and opportunities in addressing
the needs of young newborn infants, including PTD and LBW
infants.
Discussion
HIV infection and the newborn infant
Early infant diagnosis leading to prompt initiation of effective
cART can prevent postnatal HIV disease progression. Until
recently, infant diagnosis focused on those between four and
six weeks of age after preliminary data from the Children with
HIV Early Antiretroviral (CHER) trial results were released
in 2007. This study showed that commencing antiretroviral
Cotton MF et al. Journal of the International AIDS Society 2015, 18(Suppl 6):20271
http://www.jiasociety.org/index.php/jias/article/view/20271 | http://dx.doi.org/10.7448/IAS.18.7.20271
1
therapy (ART) at a median of 7.4 weeks of age reduced mor-
tality by 76% and HIV disease progression by 75% in infants
with a baseline CD4% ]25%. However, less well appreciated
was data suggesting rapid disease progression preceding
ART initiation in the trial. Over the three to four weeks
between diagnosis and study entry, seven HIV-infected infants
(1.25% of those identified) had already died, 16 (2.8%) had
developed signs of advanced HIV disease and almost 20%
had a CD4% B25% [3]. These observations, during this short
period, suggest that seven weeks of age for ART initiation
is too late for many. In a subsequent study from the two
CHER trial sites between 2007 and 2010, 62% of 250 infants
already had advanced HIV disease when ART was initiated by
12 weeks of age, again illustrating rapid disease progression in
early infancy [4]. Impetus for a birth PCR (in addition to a PCR
later on) is the awareness that most in utero infection can be
detected on the first day of life, which could allow earlier
linkage to care and less attrition [5].
Infants most at risk for acquiring HIV and who could benefit
from both enhanced prophylaxis and early diagnosis are those
whose mothers either seroconverted late in pregnancy or had
not attained viral suppression on ART. Under these circum-
stances, there is both a need for early diagnosis to establish
infection status as soon as possible after birth and to establish
enhanced post-exposure prophylaxis for the infants. These
numbers can be substantial. For example, in South Africa,
where a rapid antibody test is repeated at week 32 and
in labour in pregnant women who initially tested negative,
3.3% of mothers had acute seroconversion, accounting for
26% of vertically infected infants in a public program [6].
PTD and being small for gestational age (SGA) are risk factors
for intrapartum HIV transmission, probably because of shorter
exposure to antenatal cART and more immature mucosal
barriers [79].
For infants whose mothers were diagnosed with HIV late
in pregnancy, the best possible post-exposure prophylaxis is
required, accompanied by caregiver counselling on prophy-
laxis administration to avoid medication errors. A prophylaxis
regimen comprising zidovudine plus three doses of nevirapine
is now recommended for infants at high risk for vertical trans-
mission [10,11]. It is also essential to continue prophylaxis
in infants whose mothers may be failing ART. In many settings,
it is standard practice to introduce cART as post-exposure
prophylaxis when there is a risk for vertical transmission
[12,13]. Although there is no evidence of enhanced preven-
tion, using cART for prevention will then continue, should
baseline tests confirm infection.
Early cART initiation within the first few hours may have
benefits beyond preventing HIV disease complications. The
report of the Mississippi baby who spent almost two years
without detectable plasma viremia after starting cART at
31 hours of age suggests that early therapy could limit HIV
reservoir size, which may have a dramatic impact on the
lifelong course of HIV infection [14,15]. The experience with
the Mississippi baby has increased motivation for a birth PCR
and cART for both prophylaxis and treatment in newborn
infants [15].
Low birth weight, premature and SGA infants
LBW is defined as a birth weight below 2500 g. Its global
prevalence is 15.5%, accounting for about 20 million infants
born each year, 96.5% of them in developing countries [16].
Contributing factors are prematurity, defined as birth before
37 completed weeks of gestation, and being SGA, defined as
a birth weight below the 10th centile for gestational age. PTD
accounted for 11.1% or 14.9 million babies in 2010 and is
the second most common cause of mortality below five years
of age, after pneumonia. Most PTDs occur after 32 weeks of
gestation [17]. In a survey from East Africa comprising more
than 5000 live births, 9.2% were LBW and 4% were PTD.
Compared to term delivery, gestational age below 34 weeks
gestation had a 58-fold higher death rate. Risk of death was
threefold higher for gestational age between 34 and 36 weeks,
but if also SGA mortality was 20-fold higher [18]. In a recent
South African report of neonates requiring intensive care in
Pretoria, 68% were LBW, with 8% weighing below 1000 g, 24%
between 1000 and 1499 g, and 24% between 1500 and 2000 g
[19]. In an audit of HIV-exposed preterm infants at a tertiary
neonatal unit in Cape Town between 2010 and 2011, 3.3%
had a birth weight below 1000 g and were significantly more
HIV exposed than those with a higher birth weight. Of 51
HIV-exposed infants, mean birth weight was 834 g and mean
gestational age was 28.3 weeks. Most were born by caesarean
section before active labour, with a transmission rate of
2.7% by six weeks of age [20].
PTD and LBW rates are increasing every year [21]. In 2010,
59% of SGA newborn infants were born at term and 41%
were preterm [22]. Infectious causes of SGA include maternal
malaria, varicella and syphilis [23]. Maternal tuberculosis,
prevalent in many settings where HIV is common, contributes
substantially to prematurity and LBW [24,25]. Placental causes
include abruption and infarcts; other maternal causes include
hypertension, diabetes or exposure to tobacco, alcohol or
recreational drugs [23]. HIV infection and ART contribute to
LBW, PTD and SGA [26].
Infant consequences of PTD include hypothermia, hypo-
glycaemia, respiratory distress, apnoea, intraventricular hae-
morrhage and sepsis and may complicate HIV diagnosis and
treatment.Very premature infants may require parenteral nutri-
tion and tube feeding is necessary below around 34 weeks
gestation. Gastro-oesophageal reflux occurs commonly putting
the infant at risk for apnoea and aspiration [27]. Necrotizing
enterocolitis (NEC), a potentially lethal complication often
necessitating periods without enteral feeding, is more com-
mon in HIV-infected premature infants [28]. Breastfeeding is
especially important to prevent NEC [29]. SGA infants have
additional risks of polycythaemia and neurological dysfunction
related to hypoxia [30].
Antiretrovirals for neonates
Neonates have significant differences in physiology that impact
drug disposition, so that neonatal drug absorption, distribution,
metabolism and elimination differ from that in older infants
and children. Neonatal differences in drug disposition are
even greater in premature infants [31]. Antiretrovirals (ARVs)
cannot be safely and effectively used in neonates without
being directly studied in these most vulnerable populations.
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Immaturity in gastrointestinal tract function, the unique diet
of the young infant, developmental changes in drug trans-
porter systems and the need for special formulations due
to the inability to swallow pills all impact drug absorption.
Maturational changes in body size and composition, as well
as plasma protein concentrations, will change drug distribu-
tion with age [32]. Activity of enzymes critical for drug eli-
mination such as CYP3A4 and UGT2B6 are lower in neonates
than older infants and lower in preterm than term infants.
The pattern of maturation in activity is specific for each
enzyme and isoform, with adult values generally reached by
later childhood or early adolescence [31,32].
Although cART regimens should be an essential component
of neonatal post-exposure prophylaxis and treatment regimens,
the paucity of relevant and appropriate neonatal pharmaco-
kinetic and safety data makes their use in neonates and
young infants difficult. Twenty-five ARVs have US Food and
Drug Administration (FDA) approval for children. Only six are
approved for newborn term infants, and one of these drugs
(lopinavir) is not recommended until 42 weeks post-conception
(See Table 1). Zidovudine, stavudine, lamivudine and emtricita-
bine have adequate pharmacokinetic data and oral formula-
tions for the first two weeks of life in term infants [11,33,34].
Zidovudine is the only ARV with sufficient pharmacokinetic
data from premature infants to allow development of dosing
regimens to ensure effective yet not toxic plasma concentra-
tions [35]. For infants unable to tolerate enteral feeding and
requiring parenteral drug administration, zidovudine is also
the only ARV with an intravenous formulation.
While there are several studies describing nevirapine phar-
macokinetics in neonates and young infants, these studies
were designed for prophylactic dosing regimens to maintain
trough concentrations above 0.1 mg/mL [36]. Nevirapine regi-
mens for successful treatment of HIV infection require trough
concentrations above 3.0 mg/mL, but there are no pharmaco-
kinetic studies of nevirapine in neonates with the goal of
achieving the treatment concentrations. Nevirapine is meta-
bolized mainly by CYP2B6 and CYP3A4, whose activity is low
in term neonates. The nevirapine prophylaxis studies have
shown that nevirapine clearance is low in neonates and even
lower in preterm or growth-retarded infants [36,37]. In adults,
nevirapine auto-induces its own clearance but the extent
of auto-induction on immature enzyme systems is unknown.
For infants co-infected with Mycobacterium tuberculosis and
requiring rifampicin co-treatment, nevirapine clearance is also
enhanced in African children [38]. Thus, there are fewer
antiretroviral options for co-infected newborn infants.
Raltegravir, the first commercially available integrase inhi-
bitor, illustrates many challenges and delays faced in establish-
ing safe and effective ARV dosing regimens for neonates.
The FDA approved raltegravir for adults in 2007, for children
aged 2 to 12 years in 2011 and for infants four weeks to two
years in 2013. However, safety and pharmacokinetic data for
neonates are still lacking. Raltegravir is easily transported
across the placenta and commonly included in antenatal cART
regimens where mothers are on second-line therapy or have
not attained virologic suppression towards delivery. Neonatal
washout of transplacentally acquired raltegravir is variable
and prolonged during the first days of life, as expected since
raltegravir is eliminated by UGT1A1, the same enzyme that
metabolizes bilirubin and whose activity is very low imme-
diately after birth [39]. An in vitro study has shown that
at extremely high concentrations (50 to 100 times greater
than those seen in adults receiving usual treatment doses),
raltegravir displaces bilirubin from albumin [40]. These data
suggest that a hyperbilirubinaemic newborn, especially if PTD
or LBW, receiving raltegravir could be at increased risk for
kernicterus from the displacement of bilirubin from albumin,
as was seen with sulfisoxazole [41,42]. Raltegravir dosing for
neonates will have to be carefully designed to avoid accu-
mulation to potentially dangerous plasma concentrations,
especially when neonates are premature and have LBW.While
raltegravir would be of great benefit for use in neonates for
prevention or treatment, the rigorous safety and pharmaco-
kinetic studies needed before it can be used safely in term and
preterm newborns have yet to be conducted.
Lopinavir-ritonavir is available as a liquid formulation con-
taining 42.4% alcohol by volume and 15.3% propylene glycol
by weight and volume. The FDA received a report of 10 neo-
natal cases of severe renal, metabolic and cardiac toxicities
with a single fatality after being given this lopinavir-ritonavir
liquid formulation. After this report, a recommendation was
Table 1. ARVs available for term infants in first four weeks of life and for preterm newborn infants
Term Preterm Comments
Reverse transcriptase inhibitors
Zidovudine X X IV formulation available
Lamivudine X Dosage available for first month
Emtricitabine X Dosage from 0 to 3 months
Stavudine X
Non-nucleoside reverse transcriptase inhibitors
Nevirapine X X Dosages available for prevention only
Protease inhibitors
Lopinavir-ritonavir X (Recommended only after 2 weeks of age
and 42 weeks post-conception)
If used earlier than 42 weeks post-conception age, therapeutic drug
monitoring and clinical and cardiac monitoring recommended
From Ref. [11].
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issued to avoid lopinavir-ritonavir until two weeks of age and
42 weeks post-conception [43]. It is not known whether these
toxicities were caused by excessive exposure to alcohol, pro-
pylene glycol and/or lopinavir. However, there are some
data to guide dosage in term neonates and premature and
LBW infants, should the potential benefit be thought to out-
weigh the risk [44,45]. The FDA recently approved a lopinavir-
ritonavir pellet formulation for children below three years
of age for procurement in high prevalence countries. Although
it does not contain ethanol or propylene glycol and may be
safer for infants, there is concern that newborn infants may
not be able to safely swallow the pellets [46].
Programmatic and diagnostic challenges in
newborn infants
Mothers identified as HIV positive late in pregnancy and at
delivery face a very stressful period, learning about their
own status and the real possibility that their newborn infants
may be HIV infected all in a short space of time. Resources
to facilitate counselling in this period are essential. There
is growing emphasis on the benefits of breastfeeding HIV-
exposed infants in low-income settings and ensuring that
mothers continue ARVs in the postpartum period. Feeding and
weight monitoring are particularly important in premature
and LBW infants. In many hospital settings, flash heating or
pasteurization may be used to inactivate HIV in breast milk,
while retaining nutritional value [47].
In many settings where HIV is prevalent, newborn infants
weighing above 1800 g are already sent home, if stable. There-
fore, such LBW infants are seen in primary care facilities such
as in Khayelitsha, South Africa, where 28% of HIV-exposed
infants delivered were LBW or premature (internal data).
Simplified guidelines on PCR testing of HIV-exposed infants
(high risk infants versus universal testing for all HIV-exposed
infants), indications for up-referral of clinically unwell pre-
mature HIV-exposed infants, clear weight-based algorithms on
neonatal ART dosages and routine laboratory monitoring all
require consideration in primary care settings.
Preliminary data from birth PCR testing of HIV-exposed
infants in Khayelitsha indicated a high acceptance of mothers
(99%) for testing at delivery. Standardized counselling sessions,
including information on repeat testing for neonates nega-
tive at birth, were introduced. Counselling sessions were
adapted for mother-infant pairs to support cART adherence
and appropriate dosing, together with frequent clinical re-
views during the first months of life [48]. Neonatal ART is
feasible and promotes retention in care when accompanied
by good counselling, complemented by disclosure to a treat-
ment supporter [49].
Conclusions
Neonates including LBW and PTD form a special risk group,
requiring increased recognition in the efforts to reach the
90-90-90 targets. Early diagnosis shortly after birth requires
planning and resources. There is an urgent need for safe and
effective cART regimens. Use of these drugs in this population
will require rigorous pharmacokinetic and safety studies and a
supportive clinical environment.While several studies through
the International Maternal Pediatric and Adolescent AIDS
Clinical Trials (IMPAACT) network (P1097, P1106 and P1115)
are beginning to address some of the therapeutic gaps in the
first weeks of life and in premature infants, these efforts
are insufficient. Delays between diagnosis and therapy while
waiting for infants to reach a physiological maturity sufficient
to allow dosing based on our current knowledge base cannot
be justified in term infants and may be dangerous for pre-
mature infants.
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